Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA)
Dawn Konrad-Martin, PhD, et al.
An effective treatment for some cancer is cisplatin
chemotherapy; however, a potential side effect of cisplatin
is hearing loss. This article describes a new,
comprehensive Department of Veterans Affairs program
for ototoxicity monitoring done while the Veteran
receives treatment, with the goal of preventing
or minimizing hearing loss when possible. When
appropriate, treatment changes that might minimize
hearing damage include dose reduction, omission, or substitution to a less toxic chemotherapy drug. The
approach is patient centered, with audiology and oncology
services working together to improve communication
and coordination of care between them
for the benefit of Veterans and their families.
http://dx.doi.org/10.1682/JRRD.2013.04.0092
Volume 51 Number 1, 2014
Pages 81 — 100
View HTML ¦ View PDF ¦ Contents Vol. 51, No.1
This article and any supplementary material should be cited as follows:
Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):81–100.
http://dx.doi.org/10.1682/JRRD.2013.04.0092
Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):81–100.
http://dx.doi.org/10.1682/JRRD.2013.04.0092
Go to TOP
Last Reviewed or Updated Wednesday, April 9, 2014 9:57 AM
